We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Impact of Preanalytical Factors on Calprotectin Concentration in Stool

By LabMedica International staff writers
Posted on 29 Dec 2022
Print article
Image: The BÜHLMANN fCAL ELISA is a microtiter based assay kit for determination of calprotectin in fecal samples (Photo courtesy of Bühlmann Laboratories)
Image: The BÜHLMANN fCAL ELISA is a microtiter based assay kit for determination of calprotectin in fecal samples (Photo courtesy of Bühlmann Laboratories)

In inflammatory bowel disease (IBD), fecal calprotectin measurement is increasingly important in selecting patients for diagnostic endoscopy, monitoring of disease activity, and evaluation of treatment response.

Calprotectin is a calcium-binding protein mainly produced in neutrophils. It is said to be resistant to bacterial degradation in the colon, and the literature almost unanimously states that calprotectin is stable up to seven days at room temperature without preservation buffer.

Clinical Chemists at the University Medical Center Groningen (Groningen, The Netherlands) and their colleagues from other institutions evaluated the impact of pre-analytical storage conditions on reliability of calprotectin testing using five different calprotectin immunoassays. The scientists distributed 45 frozen anonymized feces aliquots among the three participating centers. They assessed the calprotectin concentration over time under four conditions, including (a) untreated native stool stored at room temperature (NRT), (b), stool extract stored at room temperature, (c), untreated native stool stored at 4 °C, and (d), stool extract stored at 4 °C.

The five assays were: the Bühlmann fCAL turbo test (Bühlmann Laboratories AG, Schönenbuch Switzerland) is a particle-enhanced turbidimetric immunoassay performed on a COBAS 6000 e501 (Roche Diagnostics, Rotkreuz. Switzerland); the Bühlmann fCAL enzyme-linked immunosorbent assay (ELISA; Bühlmann Laboratories AG) is a sandwich-based ELISA performed and analyzed using a DS2 Dynex ELISA robot (Dynex, Chantilly, VA, USA); the CALliaGold test (Sentinel CH, Milan Italy) is a particle-enhanced turbidimetric immunoassay (PETIA) and analysis was performed using a SENTiFIT 270 Analyzer (Sysmex Europe SE, Norderstedt, Germany).

The other two assays were the EliA Calprotectin test which is a fluorescence enzyme immunoassay and the analysis was performed using the Phadia 250 (Thermo Fisher Scientific, Waltham, MA, USA); and the QUANTA Flash Calprotectin (Inova Diagnostics , San Diego, CA, USA) a chemiluminescent immunoassay and the analysis was performed on BIO FLASH (Werfen, Bedford, MA, USA).

The investigators reported that Calprotectin concentrations declined over time under all pre-analytical conditions with all assays, except for extracted feces stored at 4 °C. The rate of decline was greatest in untreated stool kept at room temperature, reaching significant difference from baseline already after one day. In extracted feces kept at room temperature, significant difference from baseline was reached after two days, and in untreated feces at 4 °C, after four days. However, the results differed significantly between assays. After four days of storage at room temperature, the mean calprotectin decline from baseline differed between 30% and 60%, dependent on the assay used. In most, but not for all samples, the CALiaGold assay produced the highest calprotectin levels, and the QUANTA flash assay, the lowest calprotectin levels.

The authors conclude that fecal calprotectin concentration in stool samples declines over time, and the rate of decline is greater at higher temperatures. In extracted feces stored at 4 °C, calprotectin is the most stable. It is assay-dependent how long extracted feces stored at 4 °C give reliable test results. The study was published in the November 2022 issue of The Journal of Applied Laboratory Medicine.

Related Links:
University Medical Center Groningen
Bühlmann Laboratories
Roche Diagnostics
Dynex
Sentinel CH
Sysmex
Thermo Fisher Scientific 
Inova Diagnostics 
Werfen 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A massive study has identified new biomarkers for renal cancer subtypes, improving diagnosis and treatment (Photo courtesy of Jessica Johnson)

Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes

Renal cell carcinomas (RCCs) are notably diverse, encompassing over 20 distinct subtypes and generally categorized into clear cell and non-clear cell types; around 20% of all RCCs fall into the non-clear... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more